Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ∼12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, which leads to blocked cellular differentiation. Enasidenib (AG-221/...

詳細記述

保存先:
書誌詳細
出版年:Blood
主要な著者: Stein, Eytan M., DiNardo, Courtney D., Pollyea, Daniel A., Fathi, Amir T., Roboz, Gail J., Altman, Jessica K., Stone, Richard M., DeAngelo, Daniel J., Levine, Ross L., Flinn, Ian W., Kantarjian, Hagop M., Collins, Robert, Patel, Manish R., Frankel, Arthur E., Stein, Anthony, Sekeres, Mikkael A., Swords, Ronan T., Medeiros, Bruno C., Willekens, Christophe, Vyas, Paresh, Tosolini, Alessandra, Xu, Qiang, Knight, Robert D., Yen, Katharine E., Agresta, Sam, de Botton, Stephane, Tallman, Martin S.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2017
主題:
Clinical Trials and Observations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5572791/
https://ncbi.nlm.nih.gov/pubmed/28588020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-04-779405
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料